Abstracts tagged "pregnancy"

Abstract Number: 0586 • ACR Convergence 2023
Therapeutic Drug Monitoring of Azathioprine and Tacrolimus in SLE Pregnancies: Preliminary Results from the LEGACY Cohort
Reem Farhat¹, Arielle Mendel², Isabelle Malhamé³, Joo Young (Esther) Lee⁴, Luisa Ciofani⁵, Sasha Bernatsky⁶ and Evelyne Vinet², ¹McGill University, Montréal, QC, Canada, ²McGill University Health Centre, Montréal, QC, Canada, ³McGill University Health Centre, Montreal, QC, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵McGill University Health Center, Montreal, QC, Canada, ⁶Research Institute of the McGill University Health Centre, Montreal, QC, Canada
Background/Purpose: Pregnant SLE women still face an unacceptably high risk of maternal and fetal morbidity, particularly when their disease is active. How to personalize SLE…
Abstract Number: 1361 • ACR Convergence 2023
Effect of Zen/Doria Remission and Glucocorticoid Dosage on the Pregnancy Outcome of SLE: Retrospective Study in Two Japanese Tertiary Referral Centers
Takehiro Nakai¹, Nanase Honda², Sho Fukui³, Ayako Kitada¹, Naoto Yokogawa⁴ and Masato Okada¹, ¹St. Luke's International Hospital, Tokyo, Japan, ²Tokyo Metropolitan Tama Medical Center, Fuchu-shi, Japan, ³Brigham and Women's Hospital, Boston, MA, ⁴Tokyo Metropolitan Tama Medical Center, Taito City, Tokyo, Japan
Background/Purpose: Achieving remission is one of the treatment targets in the lupus care and it is also important in preventing the prevalence of adverse pregnancy…
Abstract Number: 0191 • ACR Convergence 2023
Reproductive Health Discussions Between Rheumatology Providers and Systemic Lupus Erythematosus Patients: A Survey of English and Spanish-Speaking Patients
Meredith Xepoleas¹, Martha Delgado², Jack Rodman³, Julia Simard⁴, Sandy Lee⁵ and Leanna Wise⁶, ¹Keck School of Medicine of University of Southern California, Los Angeles, CA, ²LAC+USC/Keck School of Medicine, Los Angeles, CA, ³University of Southern California, Los Angeles, CA, ⁴Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA, ⁵University of Southern California, Walnut, CA, ⁶LAC+USC/Keck Medicine of USC, Pasadena, CA
Background/Purpose: Systemic lupus erythematosus (SLE) primarily affects women of childbearing age, with a higher burden in non-Caucasian populations. Due to the increased risk of adverse…
Abstract Number: 0722 • ACR Convergence 2023
Acute Cardiovascular Events in Autoimmune Rheumatic Disease Pregnancies
Rashmi Dhital¹, Rebecca Baer², Monica Guma², Kenneth Kalunian², Accelerating Medicines Partnership Program RA SLE Network³ and Christina Chambers², ¹UC San Diego, San Diego, CA, ²University of California San Diego, La Jolla, CA, ³Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: Cardiovascular diseases (CVDs) complicate 1-4% of pregnancies. Autoimmune rheumatic diseases (ARDs) are associated with a 1.5 to 3-fold higher CVD risk. Similarly, antiphospholipid syndrome…
Abstract Number: 1362 • ACR Convergence 2023
Improving Reproductive Health Counseling for Pediatric Adolescent Females Prescribed Teratogenic DMARDs
Rina Ferguson¹, Itay Marmor² and Maleewan Kitcharoensakkul¹, ¹Washington University/B-JH/SLCH Consortium, St. Louis, MO, ²Dana-Dwek Children's Hospital, Hod Hasharon, Israel
Background/Purpose: Several rheumatologic medications routinely prescribed to adolescent females are teratogenic. However, there is no standard method to educate our patients and their families about…
Abstract Number: 0194 • ACR Convergence 2023
Reproductive Health Conversations with a Primarily Hispanic Systemic Lupus Erythematosus Population: Influences and Barriers
Zarmeen Zaheer¹, Martha Delgado², Jack Rodman³, Julia Simard⁴, Sandy Lee⁵ and Leanna Wise⁶, ¹Huntington Health, Tampa, FL, ²LAC+USC/Keck School of Medicine, Los Angeles, CA, ³University of Southern California, Los Angeles, CA, ⁴Department of Epidemiology & Population Health, Stanford University School of Medicine, Stanford, CA, ⁵University of Southern California, Walnut, CA, ⁶LAC+USC/Keck Medicine of USC, Pasadena, CA
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease most commonly seen in women of childbearing age, with a greater burden in non-Caucasian populations. The…
Abstract Number: 0903 • ACR Convergence 2023
Effects of Hydroxychloroquine on Maternal Outcomes in Pregnant Patients with Systemic Lupus Erythematous
Yurilu Gonzalez¹ and Irene Tan², ¹Albert Einstein Medical Center, Wyncote, PA, ²Einstein Medical Center Philadelphia, Bala Cynwyd, PA
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease, that affects women of childbearing age. SLE is a high-risk condition in pregnant patients due…
Abstract Number: 1364 • ACR Convergence 2023
Both Low and High 25(OH)-Vitamin D Levels Increase Adverse Pregnancy Outcomes in Systemic Lupus Erythematosus
Nima Madanchi¹, Andrea Fava², Daniel Goldman³, Larry Magder⁴, Rebecca Jacobson¹ and Michelle Petri³, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Department of Medicine, Division of Rheumatology, Johns Hopkins University School of Medicine, Timonium, MD, ⁴University of Maryland, Baltimore, MD
Background/Purpose: We evaluated the role of maternal 25(OH)-vitamin D in adverse pregnancy outcomes in systemic lupus erythematosus (SLE). Methods: We used a longitudinal cohort that…
Abstract Number: 0463 • ACR Convergence 2023
Appropriate Preconception Care Improves Pregnancy Outcomes in SLE Patients
Hiromi Shimada¹, Rina Mino², Risa Wakiya³, Shusaku Nakashima³, Taichi Miyagi⁴, Yusuke Ushio⁵, Koichi Sugihara⁶, Mao Mizusaki³, Kanako Chujo⁷, Ryoko Kagawa⁵, Hayamasa Yamaguchi⁵, Tomohiro Kameda³ and Hiroaki Dobashi³, ¹Kagawa University, Kagawa, Japan, ²Kagawa University, Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa, Japan, ³Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan, ⁴Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Kidagun, Japan, ⁵Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University, Miki-cho, Kita-gun, Japan, ⁶Kagawa University, Miki-cho, Kita-gun, Japan, ⁷Kagawa University, Miki, Kita District, Kagawa, Japan
Background/Purpose: Pregnancies complicated by systemic lupus erythematosus (SLE) are known to be at high risk for adverse pregnancy outcomes (APOs). Previous studies have shown that…
Abstract Number: 0979 • ACR Convergence 2023
Use and Discontinuation of Tumour Necrosis Factor Inhibitors Among Pregnant Women with Chronic Inflammatory Diseases
Leah K. Flatman¹, Sasha Bernatsky², Isabelle Malhamé³, Yvan St. Pierre², Olga Basso¹, Anick Bérard⁴ and Evelyne Vinet⁵, ¹McGill University, Montreal, QC, Canada, ²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³McGill University Health Centre, Montreal, QC, Canada, ⁴University of Montreal, Montreal, QC, Canada, ⁵McGill University Health Centre, Montréal, QC, Canada
Background/Purpose: Early consensus statements recommended discontinuing tumour necrosis factor inhibitors (TNFi) during pregnancy. Despite new guidelines recommending against this, the choice to stop TNFi pre-conception…
Abstract Number: 1571 • ACR Convergence 2023
Tocilizumab in Pregnant Takayasu Arteritis – The Use of Tocilizumab at Conception and Throughout Pregnancy in Those with Takayasu Arteritis
Nurul Aulia Zakaria¹, Andrew Porter², Robert Maughan², Charis Pericleous², Japna Satara³, Matthew Colquhoun⁴, Priyanka Agrawal³, jan Nouza³, Harold Wilson-Morkeh³, Taryn Youngstein² and Justin Mason², ¹National Heart & Lung Institute, Imperial College London, Kuantan, Malaysia, ²National Heart & Lung Institute, Imperial College London, London, United Kingdom, ³Rheumatology, Hammersmith Hospital, London, United Kingdom, ⁴Department of Rheumatology, Imperial College Healthcare Trust, London, United Kingdom
Background/Purpose: Takayasu arteritis (TA) is a large vessel vasculitis predominantly affecting female of reproductive age. Tocilizumab (TCZ) is frequently used in synthetic DMARD refractory cases.…
Abstract Number: 0464 • ACR Convergence 2023
Adverse Pregnancy Outcomes in Sjogren’s Disease Compared to Controls: An Interdisciplinary Approach with Maternal Fetal Medicine
Lauren Tesoriero¹, Jennifer Kidd¹, Julie Piccione¹, Izmirly peter², Meredith Akerman¹, Steven Carsons¹, Patricia Rekawek¹ and Julie Nusbaum¹, ¹NYU Long Island School of Medicine, Mineola, NY, ²NYU, New York, NY
Background/Purpose: Outside of the known association of Ro antibody with congenital heart block (CHB), little is known about adverse maternal outcomes, and even less about…
Abstract Number: 0986 • ACR Convergence 2023
Medication Use Patterns and Factors Associated with Abnormal Pregnancy Outcomes in Patients with Rheumatoid Arthritis in Korea
Yeo-Jin Song¹, Soo-Kyung Cho¹, Yu-Seon Jung², Jihyun Keum³, Sun-Young Jung², Dae Hyun Yoo⁴ and Yoon-Kyoung Sung¹, ¹Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²College of Pharmacy, Chung-Ang University, Seoul, South Korea, ³Department of Obstetrics and Gynecology, College of Medicine, Hanyang University, Seoul, South Korea, ⁴Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
Background/Purpose: As female patients constitute a significant proportion of rheumatoid arthritis (RA) cases, pregnancy management is crucial for women with RA. This study aimed to…
Abstract Number: 1681 • ACR Convergence 2023
Tacrolimus Use in SLE Pregnancy and Its Effect on Pregnancy Outcomes: Retrospective Study in Two Japanese Tertiary Referral Centers
Takehiro Nakai¹, Nanase Honda², Eri Soga², Sho Fukui³, Ayako Kitada¹, Naoto Yokogawa⁴ and Masato Okada¹, ¹St. Luke's International Hospital, Tokyo, Japan, ²Tokyo Metropolitan Tama Medical Center, Tama, Japan, ³Brigham and Women's Hospital, Boston, MA, ⁴Tokyo Metropolitan Tama Medical Center, Taito City, Tokyo, Japan
Background/Purpose: Tacrolimus is one of the major treatment options of systemic lupus erythematosus (SLE) and is thought to be pregnancy compatible medication. Since little is…
Abstract Number: 0466 • ACR Convergence 2023
Impact of Postpartum on Patients with Inflammatory Rheumatic Diseases: The P2Rheum Study
Marie Hornez¹, Anna Molto², Maxime Leroy³, beatrice banneville⁴, Rakiba Belkhir⁵, elodie chauvet⁶, Marion Couderc⁷, Emanuelle Dernis⁸, sandra Desouches⁹, Valerie Devauchelle¹⁰, Aline Frazier-Mironer¹¹, Laure Gossec¹², elisabeth Gervais¹³, Hubert Marotte¹⁴, Christophe Richez¹⁵, Jeremie SELLAM¹⁶, Raphaele Seror¹⁷, Véronique Le Guern¹⁸, Gaelle Guettrot-Imbert¹⁸, Nathalie Costedoat-Chalumeau¹⁹, Rene-Marc Flipo²⁰ and Jean-Guillaume Letarouilly²¹, ¹University of Lille, Lille, France, ²HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ³CHU Lille - Department of Biostatistics, Lille, France, ⁴Sorbonne universite and Pitié Salpêtrière Hospital, la Garenne Colombes, France, ⁵Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin-Bicêtre, France, ⁶CH Perpignan, Perpignan, France, ⁷CHU Gabriel Montpied, Clermont Ferrand, France, ⁸CH Le Mans, Le Mans, France, ⁹Hôpital Saint Antoine, Assistance Publique Hôpitaux de Paris, Paris, France, ¹⁰UBO, Brest, France, ¹¹APHP Lariboisiere Hospital, Paris, France, ¹²Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France, ¹³CHU Poitiers, Poitiers, France, ¹⁴CHU Saint-Etienne, Saint-Etienne, France, ¹⁵Université de Bordeaux, Bordeaux, France, ¹⁶Sorbonne Université APHP, Paris, France, ¹⁷University Hospital Paris Saclay, Le Kremlin-Bicêtre, France, ¹⁸APHP Hôpital Cochin, Paris, France, ¹⁹Inserm DR Paris 5, Paris, France, ²⁰La Lettre du Rhumatologue, Paris, France, ²¹CHU Lille, Lille, France
Background/Purpose: There are limited data on the impact of the postpartum period (PP) on the activity of inflammatory rheumatic disorders (IRD), and the data available…

« Previous Page
1
…
4
5
6
7
8
…
19
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].